Alpha generation platform

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Retrieved on: 
Wednesday, November 1, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Chandos Chair of Medicine and Anatomy, FDA, CAR, CGMP, Associate, Ovarian cancer, Therapy, Roswell, II, Research and development, Translational research, Department of Medicine – University of Pamplona, Multimedia, Roswell Park Comprehensive Cancer Center, Senior, Alpha generation platform, Leukemia, Woman, Patient, Biomedicine, Lymphoma, Pharmaceutical industry, Roswell Park, Generate

In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Key Points: 
  • In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
  • View the full release here: https://www.businesswire.com/news/home/20231101307318/en/
    Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors.
  • The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.
  • It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

Generate:Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

Retrieved on: 
Thursday, September 14, 2023
Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Biomedicine, Asthma, Alpha generation platform, Probability, Drug development, University, Therapy, SARS-CoV-2, Infection, Enzyme, ARCH Venture Partners, COVID, Mirae Asset Financial Group, MD Anderson Cancer Center, Pandemic, Clinical trial, ADIA, Flagship Pioneering, Patient, Biology, Abu Dhabi Investment Office, Abu Dhabi Investment Authority, Disease, Pharmaceutical industry, Vaccine, Management, Amgen, Generate

Generate:Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, today announced that it has raised $273 million in Series C financing.

Key Points: 
  • Generate:Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, today announced that it has raised $273 million in Series C financing.
  • This financing round attracted many new investors including Amgen; NVentures, NVIDIA’s venture capital arm; MAPS Capital (Mirae Asset Group); and Pictet Alternative Advisors.
  • The company will leverage Series C funding to further its pipeline, including filing multiple INDs in 2024 and initiating multiple clinical trials annually thereafter.
  • Additionally, the company will fully validate the breadth of its platform capabilities and establish its leadership in de novo therapeutic development.

Generate:Biomedicines Unveils State-of-the-art CryoEM Laboratory to Accelerate Generative AI Drug Discovery and Development

Retrieved on: 
Monday, June 26, 2023
Research, Technology, Other Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Other Science, Biomedicine, Alpha generation platform, Therapy, Cognitive Research Corporation Driving Simulator, Thermo Fisher Scientific, Doctor of Philosophy, Cryogenic electron microscopy, Protein, Laboratory, Non-Euclidean geometry, Virus, JEOL, Microscope, Fine chemical, Generate

Generate:Biomedicines today announced the unveiling of its cryogenic electron microscopy (CryoEM) laboratory in Andover, Massachusetts.

Key Points: 
  • Generate:Biomedicines today announced the unveiling of its cryogenic electron microscopy (CryoEM) laboratory in Andover, Massachusetts.
  • As a result, the company will better understand the precise manner in which therapeutics interact with their intended targets, accelerating drug discovery processes and providing a competitive advantage in the de novo therapeutic protein field.
  • With the unveiling of this new CryoEM laboratory, the company will add a powerful new structural determination tool to the repertoire of its proprietary in-house machine learning models.
  • By deploying CryoEM to explore novel proteins of interest, the new laboratory will yield terabytes of valuable data each day to add to the rapidly growing body of information available to The Generate Platform.

Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI

Retrieved on: 
Thursday, April 27, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Other Technology, Research, Hospitals, Science, Biomedicine, Translation, Alpha generation platform, Drug development, University, Therapy, Innovation system, Advance, Multimedia, Monroe Dunaway Anderson, Translational research, II, MD Anderson Cancer Center, Organization, MD, Patient, Anderson, Drug discovery, Pharmaceutical industry, Generate

Generate:Biomedicines and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.

Key Points: 
  • Generate:Biomedicines and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230425006147/en/
    Under the co-development and commercialization agreement, MD Anderson and Generate:Biomedicines will each contribute toward creating optimized, potentially best-in-class therapeutics that can rapidly advance into proof-of-concept clinical trials.
  • TRACTION is a core component of MD Anderson’s Therapeutics Discovery division that deploys a fully integrated translational biology engine to overcome traditional challenges in oncology drug discovery.
  • “Our collaboration with MD Anderson is an embodiment of innovative and cooperative research purposed to maximize the clinical impact of new therapeutics in oncology,” said Generate:Biomedicines' Chief Medical Officer, Alex Snyder, M.D.

LS Power Announces Key Senior Management Promotions

Retrieved on: 
Tuesday, April 26, 2022
Alpha generation platform, Fuel, NRG Energy, Weather, Energy management, Critical Role, Solution, NEW, Wind, Multimedia, Industry, Acquisition, Renewable energy

NEW YORK, April 26, 2022 /PRNewswire/ -- LS Power today announced executive leadership changes designed to further align the company's efficient and flexible gas-fired generation fleet with its focus on accelerating the decarbonization of the U.S. energy sector and greater economy.

Key Points: 
  • As part of this effort, Nathan Hanson was promoted to the new position of President, LS Power Generation.
  • Hanson, who joined LS Power in 2011, previously served as Managing Director of Energy Management and Regulatory Affairs.
  • LS Power actively invests in distributed energy resource platforms, such as CPower Energy Management, Endurant Energy and EVgo, as well as Waste-to-Renewable Generation and Fuel initiatives.
  • Across its efforts, LS Power has raised in excess of$48 billionin debt and equity financing to support North American infrastructure.

CLS and SIGTech Collaborate to Offer Quantitative Analytics Capabilities

Retrieved on: 
Tuesday, October 20, 2020
Finance, Data management, Professional services, Technology, Software, Finance, Money, Alternative investment management companies, Mathematical finance, Quantitative analysis, Valuation, Hedge fund, Investment management, Economy, Financial markets, Alpha generation platform, CLS, SIGTech

CLS, a financial market infrastructure delivering settlement, processing and data solutions, and SIGTech, a leading technology provider to quantitative investment managers, today announce a collaboration to provide CLSMarketData clients with access to SIGTechs back testing environment and analytics platform.

Key Points: 
  • CLS, a financial market infrastructure delivering settlement, processing and data solutions, and SIGTech, a leading technology provider to quantitative investment managers, today announce a collaboration to provide CLSMarketData clients with access to SIGTechs back testing environment and analytics platform.
  • Masami Johnstone, Head of Information Services, CLS, said: The collaboration with SIGTech is a revolutionary step forward for understanding FX market dynamics using a sophisticated quantitative method.
  • Find out more: cls-group.com/products/data/clsmarketdata/
    SIGTech offers a state-of-the-art cloud-hosted analytics platform that helps investment managers conduct cutting-edge quantitative research and multi-asset systematic investing.
  • Founded in 2019, SIGTech has been chosen by asset managers, hedge funds and universities around the world as their trusted technology provider in quantitative finance.

QuantConnect Increases Access to Alpha Streams Market

Retrieved on: 
Thursday, August 27, 2020
Finance, Data management, Professional services, Small business, Technology, Finance, Money, Economy, Financial markets, Free and open-source software, QuantConnect, Investment, Algorithmic trading, Alpha, Alpha generation platform

QuantConnect today announced expanded access to its pioneering Alpha Streams market, the worlds first marketplace for alpha where funds can shop for and license algorithmic trading strategies.

Key Points: 
  • QuantConnect today announced expanded access to its pioneering Alpha Streams market, the worlds first marketplace for alpha where funds can shop for and license algorithmic trading strategies.
  • Alphas licensed and deployed on the QuantConnect platform makes institutional-grade alpha available to a wider audience, leveling the playing field for smaller funds.
  • QuantConnects Alpha Streams market covers equities, foreign exchange, and futures markets, and is followed by firms with cumulative AUM totaling more than $65 billion.
  • With Alpha Streams, the worlds first marketplace for alpha, QuantConnect connects its community to institutional clients in order to supply quants with recognition and revenue for their ideas.

QuantConnect Launches Free Trial Periods for Alpha Streams Marketplace Strategies

Retrieved on: 
Wednesday, February 26, 2020
Other Professional Services, Software, Finance, Banking, Data management, Professional services, Technology, Other Technology, Economy, Finance, Money, Free and open-source software, QuantConnect, Mathematical finance, Alpha, Quantitative analyst, Alpha generation platform

QuantConnect , creator of the worlds first alpha marketplace, Alpha Streams, today announced the launch of free trial periods for all algorithms listed on Alpha Streams.

Key Points: 
  • QuantConnect , creator of the worlds first alpha marketplace, Alpha Streams, today announced the launch of free trial periods for all algorithms listed on Alpha Streams.
  • We see free trial periods as a significant win-win for quants and institutions, commented Jared Broad, CEO and founder of QuantConnect.
  • I think adding free trial periods will generate more direct exposure for the communitys strategies, and translate to more licensing revenue.
  • QuantConnect is pioneering the worlds first alpha marketplace, Alpha Streams, to provide opportunities to a global community of quants and make the financial markets more efficient.